Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escalating permethrin-based treatment regimens for scabies (InfectoScab 5% and higher-concentration permethrin)
2024-513288-14-00Phase 3Authorised
- Sponsor
- InfectoPharm
- Start
- Oct 2024
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of permethrin, driponin and ivermectin in scabies (4 arms), sponsored by InfectoPharm. Primary endpoints: Primary endpoint stage II: efficacy of permethrin 10% cream regimens and Primary endpoint stage I: efficacy of InfectoScab 5% standard therapy. Planned start Oct 2024; status: authorised.
02
Drugs
permethrindriponinivermectin
03
Conditions
scabies
Beyond the preview
Go deeper on 2024-513288-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513288-14-00.